Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act This bill expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.